|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||36.50 - 37.28|
|52 Week Range||30.90 - 37.37|
|PE Ratio (TTM)||22.82|
|Forward Dividend & Yield||1.36 (3.68%)|
|1y Target Est||N/A|
The soft-drink giant offers a solid quarterly dividend, but these three promising businesses will pay you even more to own their shares.
Wall Street is already off to a hot start in the New Year, with the Dow surging to new heights and tech giants like Amazon.com, Inc. (NASDAQ:AMZN) and Nvidia Corporation (NASDAQ:NVDA) picking up right where they left off. The term “institutional investor” covers a large spectrum of companies and firms, including mutual and pension funds, endowments, private foundations, insurance companies, large investment firms, and more. Investment institutions, which pour hundreds of millions of dollars into different stocks, often employ teams of analysts that perform expensive and highly detailed research before making large stock purchases.
A Cambridge startup led by former executives at Pfizer and Biogen has attracted $58 million in financing as it seeks to pioneer a new class of drugs that can tweak the immune system without triggering major side effects. Pandion Therapeutics announced the Series A round on Thursday along with the appointments of Anthony Coyle as CEO and Jo Viney as chief scientific officer. Coyle previously led Pfizer’s (PFE) Centers for Therapeutic Innovation, a research and development group with offices in Cambridge, New York and California, while Viney led Biogen’s (BIIB) immunology research unit.
The Zacks Analyst Blog Highlights: Pfizer, Chevron, Cisco, Las Vegas Sands and Dominion Resources
Wall Street is already off to a hot start in the New Year, with the Dow surging to new heights and tech giants like Amazon (AMZN) and Nvidia (NVDA) picking up right where they left off. But as tempting as it might be to try to find the next hot tech stock, one of the best places to start searching for 2018's top picks might be where the massive institutional investors put their money.
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? On October 25, 2017, Vertex Pharmaceuticals (VRTX) announced positive top-line results from its open-label Phase 3 trial that evaluated Orkambi in 60 children suffering with cystic fibrosis (or CF) who have two copies of the F508del mutation. The trial reached its primary endpoint of safety, and Orkambi demonstrated improvement in secondary endpoints such as nutritional status and sweat chloride.